Jocelyn Solis-Moreira

Feature Writer

B.Sc. Integrative Neuroscience, M.Sc. Psychology

Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood. She is adept at translating and summarizing complex study findings in all medical fields with a particular interest in neurodegenerative diseases, cancer research, infectious diseases, and public health. As a freelance writer, her work spans from news articles and feature articles to evergreen explainers across many publications. Her overall goal is to make science accessible for all.

Articles from Jocelyn

The neurological effects of COVID-19

What is the relationship between COVID-19 and the brain? A new review published in Tropical Biomedicine summarizes the key findings on how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe COVID-19 infection, disrupts brain activity and produces a range of long-term neurological disorders.

10 Oct 2021

Accumulation of SARS-CoV-2 mutations reduces sensitivity to neutralizing antibodies

In a new study, researchers discovered that SARS-CoV-2 mutations accumulate, especially in immunocompromised patients.

10 Oct 2021

After 5 months, Pfizer-BioNTech COVID vaccine remains highly protective against hospitalization and death

The study "Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study" is published in the journal The Lancet.

7 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Study suggests shingles vaccine reduces the risk for COVID-19

People who get the shingles vaccine may have a lower risk of being diagnosed and hospitalized with coronavirus disease 2019 (COVID-19), according to a new medRxiv* preprint study. In about 150,000 people over the age of 50, vaccination for shingles was associated with a 32% reduced risk of severe COVID-19 infection.

5 Oct 2021

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.

30 Sep 2021

Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial

Coronavirus research has shown that higher viral loads are associated with severe COVID-19 infection. But new results from the phase III Coronavirus Efficacy (COVE) clinical trial find the Moderna vaccine reduces severe acute respiratory coronavirus 2 (SARS-CoV-2) viral load and viral shedding.

30 Sep 2021

Model predicts SARS-CoV-2 spread in vaccinated vs. unvaccinated populations

A modeling study led by Kuan-lin Huang of the Icahn School of Medicine at Mount Sinai in New York suggests that getting vaccinated and taking preventative measures such as social distancing and mask-wearing is the most effective way to curb the spread of severe acute respiratory coronavirus 2 (SARS-CoV-2).

29 Sep 2021

Research finds increases in 'pandemic brain' after COVID-19 lockdowns

Chances are, the COVID-19 pandemic has affected your health — even if you have never been infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to new research from Harvard Medical School, the stress of isolation from lockdown and stay-at-home measures is making people sick.

29 Sep 2021

COVID-19 vaccine effectiveness barely affected by Delta variant, research suggests

Has the Delta (B.1.617.2) variant reduced vaccine effectiveness? If you ask Ian Foster of Argonne National Laboratory and colleagues, the answer is not really. New research published in the preprint medRxiv* server suggests vaccines approved in the United States are stable and well-performing.

27 Sep 2021